A lesser-known type of breast cancer is on the rise among women in the U.S.—highlighting the need for us to pay closer attention to it.
An estimated 33,600 women will be diagnosed with lobular breast cancer or invasive lobular carcinoma (ILC) this year, according to new projections by the American Cancer Society (ACS).
“Although lobular breast cancer accounts for a little over 10 percent of all breast cancers, the sheer number of new diagnoses each year makes this disease important to understand,” said report author Angela Giaquinto, associate scientist at ACS, in a statement.
“Invasive lobular breast cancer is very understudied, probably because of a very good short-term prognosis.
Do you have a question about lobular breast cancer?
In the United States, a less well-known form of breast cancer is becoming more common in women. A. —underscoring the necessity for us to give it more consideration.
According to new estimates from the American Cancer Society (ACS), 33,600 women will receive a diagnosis of invasive lobular carcinoma (ILC) or lobular breast cancer this year.
According to the report, between 2012 and 2021, the incidence rates of ILC, which begins in the breast’s milk-producing glands, rose more sharply (2.8% annually) than the combined rates of all other breast cancers (0.8% annually).
“The sheer volume of new diagnoses each year makes it important to understand lobular breast cancer, even though it makes up just over 10 percent of all breast cancers,” said ACS associate scientist and report author Angela Giaquinto in a statement.
Furthermore, compared to the most prevalent form of breast cancer, invasive ductal carcinoma (IDC), ILC has substantially lower survival rates after seven years, underscoring the urgent need to advance prevention and early detection measures that specifically target this subtype. “”.
The authors stress that in order to increase the likelihood of better patient outcomes, this is necessary.
According to the study’s authors, ILC is frequently mixed with the more popular IDC in research and clinical trials, which can mask many of its own important, distinctive growth and appearance traits.
The authors of the study stated in the paper that “ILC has distinctive characteristics that can contribute to delayed detection, resistance to therapy, and poorer prognosis for advanced disease.”.
“Identifying risk factors, facilitating treatment efficacy, and advancing our understanding of metastatic mechanisms could all improve outcomes for the growing number of women affected by ILC by distinguishing it from ductal carcinoma in research and clinical trials.”. “.”.
Similar to a pattern observed in other types of breast cancer, the U. S. . Additionally, the report discovered that women of Asian American and Pacific Islander heritage experienced the steepest increase in ILC incidence, rising 4–4% annually between 2012 and 2021.
In general, Black women have the second-highest incidence of ILC, while White women have the highest.
In the first seven years after diagnosis, and for localized-stage disease, the survival rate for women with ILC is marginally higher than that of ductal breast cancer; however, ten years after diagnosis, the survival rate is lower for both regional and distant-stage disease.
The low level of research on invasive lobular breast cancer is likely due to its excellent short-term prognosis. According to a statement from author Rebecca Siegel, senior scientific director at ACS, “however, at ten years, these women with metastatic disease are half as likely to be alive as their counterparts with ductal cancer, probably because of the unique spread and resistance to therapy.”.
“Our study highlights the need for a lot more data on lobular cancers in general, including genetic research and clinical trial data, in order to improve outcomes for the growing number of women who have this cancer.”. “”.
For further comment, Newsweek has contacted the researchers.
Send us an email at health@newsweek . com if you have a question about lobular breast cancer or a tip for a health story that Newsweek should cover.
Citation.
